Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A...

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Neodymium YAG laser peripheral iridotomy (LPI) is a common procedure for angle-closure glaucoma.
• Post-LPI inflammation requires effective management to ensure optimal outcomes and patient comfort.

Purpose of the Study:

• To compare the safety and efficacy of 0.1% nepafenac and 0.09% bromfenac eye drops in managing post-LPI inflammation.
• To assess patient-reported comfort levels with both topical anti-inflammatory agents.

Main Methods:

• A single-center, randomized controlled trial involving 160 eyes of patients with primary angle-closure suspect (PACS) or primary angle closure (PAC).
• Patients received either 0.1% nepafenac thrice daily or 0.09% bromfenac twice daily for two weeks post-LPI.
• Outcomes included inflammation control, patient comfort (Glaucoma Symptom Scale and Likert scale), and need for repeat LPI.

Main Results:

• Both 0.09% bromfenac and 0.1% nepafenac demonstrated comparable efficacy in controlling post-LPI inflammation (P=0.09).
• Patients using nepafenac reported significantly higher comfort levels, with less burning, smarting, and stinging compared to bromfenac (P=0.01).
• The need for repeat LPI was similar between groups (10.0% vs. 15.4%, P=0.22).

Conclusions:

• Topical 0.09% bromfenac is noninferior to 0.1% nepafenac for controlling inflammation after LPI in patients with PACS and PAC.
• 0.1% nepafenac may offer superior patient-reported comfort compared to 0.09% bromfenac following LPI.